Dean Slagel, Director at Cara Therapeutics, Inc. (CARA), sold 188,811 shares at $10.00 ($1.9M) on 2015-05-15, disclosed to the SEC on 2015-05-19.
Open-market sale of $1.9M CARA by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $10.00 | 73,600 | $736K | 38.9% |
| 2 | $10.04 | 82,945 | $833K | 44.0% |
| 3 | $10.00 | 32,266 | $323K | 17.1% |
| Total | $10.02 avg | 188,811 | $1.9M | 100% |
| Filing → |